Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the appointment of Catherine Bovenizer as the Company's Vice President of Finance, Chief Accounting Officer. Ms. Bovenizer brings over 20 years of experience in finance and accounting to the position with Apricus. She will report directly to Richard Pascoe, Apricus' Chief Executive Officer, effective immediately.
"We are pleased to have Cath join the Apricus senior management team in this newly created finance and accounting role. Her years of experience in finance and accounting, particularly with biopharmaceutical companies in transition, will be critical for our financial management and reporting needs as our focus shifts towards advancing our innovative product pipeline into the next stages of clinical development and managing our cash in-flows from our marketed erectile dysfunction treatment, Vitaros®," said Mr. Pascoe.
Ms. Bovenizer stated, "I am excited to join Apricus during this transformational stage, as the Company advances clinical development for two novel product candidates and seeks to further leverage Vitaros. I look forward to leading the finance and accounting functions at Apricus and working closely with Rich and the rest of the senior team to drive the growth and future success of the Company."
Ms. Bovenizer has over 20 years of financial and public accounting experience for both private and publicly-traded companies. For 15 of those years, Ms. Bovenizer has been with companies in the biopharmaceutical industry, most recently holding the position of Executive Director and Controller with Ambit Biosciences, where she was responsible for leading Ambit's internal IPO efforts and participated in Ambit's successful sale to Daiichi Sankyo. Prior to Ambit, Ms. Bovenizer held senior director/controller roles with biopharmaceutical companies, including Senomyx, Ligand Pharmaceuticals and GeneFormatics. Ms. Bovenizer graduated magna cum laude with a B.A. in Economics, Accounting and Literature from Claremont McKenna College.
- See more at: http://globenewswire.com/news-release/2015/01/12/696637/10115013/en/Apri...
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced the appointment of Catherine Bovenizer as the Company's Vice President of Finance, Chief Accounting Officer. Ms. Bovenizer brings over 20 years of experience in finance and accounting to the position with Apricus. She will report directly to Richard Pascoe, Apricus' Chief Executive Officer, effective immediately.
"We are pleased to have Cath join the Apricus senior management team in this newly created finance and accounting role. Her years of experience in finance and accounting, particularly with biopharmaceutical companies in transition, will be critical for our financial management and reporting needs as our focus shifts towards advancing our innovative product pipeline into the next stages of clinical development and managing our cash in-flows from our marketed erectile dysfunction treatment, Vitaros®," said Mr. Pascoe.
Ms. Bovenizer stated, "I am excited to join Apricus during this transformational stage, as the Company advances clinical development for two novel product candidates and seeks to further leverage Vitaros. I look forward to leading the finance and accounting functions at Apricus and working closely with Rich and the rest of the senior team to drive the growth and future success of the Company."
Ms. Bovenizer has over 20 years of financial and public accounting experience for both private and publicly-traded companies. For 15 of those years, Ms. Bovenizer has been with companies in the biopharmaceutical industry, most recently holding the position of Executive Director and Controller with Ambit Biosciences, where she was responsible for leading Ambit's internal IPO efforts and participated in Ambit's successful sale to Daiichi Sankyo. Prior to Ambit, Ms. Bovenizer held senior director/controller roles with biopharmaceutical companies, including Senomyx, Ligand Pharmaceuticals and GeneFormatics. Ms. Bovenizer graduated magna cum laude with a B.A. in Economics, Accounting and Literature from Claremont McKenna College.
- See more at: http://globenewswire.com/news-release/2015/01/12/696637/10115013/en/Apri...
Apricus Biosciences, a biopharmaceutical company, has appointed Catherine Bovenizer to the newly-crated role of vice president of finance and chief accounting officer. She reports directly to Chief Executive Officer Richard Pascoe.
Bovenizer has over 20 years of financial and public accounting experience for both private and publicly-traded companies. For 15 of those years, Bovenizer has been with companies in the biopharmaceutical industry, most recently holding the position of executive director and controller with Ambit Biosciences, where she was responsible for leading Ambit's internal IPO efforts and participated in Ambit's sale to Daiichi Sankyo.
Prior to Ambit, Bovenizer held senior director roles with biopharmaceutical companies, including Senomyx, Ligand Pharmaceuticals, and GeneFormatics.
No comments yet